According to Zacks, “Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company’s products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. “
Other research analysts also recently issued research reports about the company. ValuEngine downgraded Invacare from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Needham & Company LLC reaffirmed a “buy” rating on shares of Invacare in a research note on Tuesday, July 14th.
Shares of NYSE IVC opened at $7.04 on Tuesday. The firm has a market capitalization of $242.31 million, a P/E ratio of -5.59 and a beta of 1.23. Invacare has a one year low of $3.90 and a one year high of $11.63. The company’s fifty day moving average is $6.95 and its two-hundred day moving average is $6.68. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.88 and a current ratio of 1.41.
Invacare (NYSE:IVC) last issued its earnings results on Wednesday, August 5th. The health services provider reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The company had revenue of $196.30 million for the quarter, compared to analyst estimates of $196.00 million. Invacare had a negative net margin of 4.82% and a negative return on equity of 9.36%. During the same period in the previous year, the firm earned ($0.31) EPS. On average, sell-side analysts forecast that Invacare will post -0.88 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Emerald Advisers LLC acquired a new position in Invacare in the 2nd quarter valued at about $39,000. Bank of Montreal Can increased its stake in shares of Invacare by 469.1% during the 2nd quarter. Bank of Montreal Can now owns 7,711 shares of the health services provider’s stock valued at $48,000 after acquiring an additional 6,356 shares during the last quarter. Metropolitan Life Insurance Co NY acquired a new position in shares of Invacare during the 1st quarter valued at about $102,000. SG Americas Securities LLC acquired a new position in shares of Invacare during the 1st quarter valued at about $98,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Invacare by 48.4% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,942 shares of the health services provider’s stock valued at $126,000 after acquiring an additional 5,526 shares during the last quarter.
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through Europe, North America/Home Medical Equipment, Institutional Products Group, and the Asia/Pacific segments.
Featured Article: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.